HS-20122

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Patients With Advanced Solid TumorsLung CancerPhase IB

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

1

Taxol

Teva

Phase 2

252

Keytruda

Merck & Co.

Phase 2

193

Camptosar

Pfizer

Phase 2

44

Tecentriq

Roche

Phase 2

45

Beyfortus

BeiGene

Phase 2

36

Halaven

Eisai

Phase 2

27

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

18

Ensacove

XXcovery Holdings, Inc.

Phase 2

19

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

210

Carboplatin AUC-5

Merck & Co.

Phase 2

1Show 28 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Phase IB1 trial

A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

Not yet recruiting·Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT07414953·400 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of HS-20122 in Patients With Advanced Solid Tumors

Recruiting·HHansoh BioMedical R&D Company·Phase 1·NCT06927570·1,050 enrolled

Lung Cancer1 trial

A PHASE Ib STUDY OF THE SAFETY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF HS-20122 COMBINED THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS

Recruiting·HHansoh BioMedical R&D Company·Phase 1·NCT07645222·396 enrolled

Details

Drug Info

Related News